Meeting/Event

Adolescent Drug Abuse Screening in General Medical Settings: Resources for Clinicians

This is Archived Content. This content is available for historical purposes only. It may not reflect the current state of science or language from the National Institute on Drug Abuse (NIDA).
View current meetings on nida.nih.gov.

Details

Neuroscience Center, Rockville, Maryland

Contact

United States

Meeting Summary

NIDA Planning Group:

  • Gaya Dowling
  • Ericka Boone
  • Wilson Compton
  • Redonna Chandler
  • Richard Denisco
  • Jacqueline Lloyd
  • Geetha Subramaniam
  • Petra Jacobs

Meeting Goals/Objectives:

  • Expectations from Meeting:
    • To discuss the current state of the science and the most effective approaches for adolescent screening in primary care settings.
    • To inform NIDA's development of an electronic adolescent drug screening tool and resource guide for clinicians.
  • Why important?
    • The high prevalence of substance abuse among adolescents calls for targeted effective intervention strategies.
    • Primary care settings provide a unique opportunity to identify substance youth and prevent their escalation to addiction or refer them to necessary treatment.

Topics Discussed:

  • Validated adolescent screening instruments
  • Considerations for different ages/developmental stages
  • Key decision points when selecting or creating a screener (e.g., purpose of the screener, risk versus severity, cut points, etc.)
  • Clinical decision support
    • What do physician's do when a screening is positive
  • Use of technology in adolescent screening tools

Take Home Messages from Talks/Group Discussions:

Outcomes from Discussion

  • Two primary evidence-based instruments discussed—CRAFFT and GAIN
  • Pros and cons of embedding drug abuse screening in broader behavioral health care screening
  • Different questions, cut-points, item hierarchies for different adolescent stages
  • Research on brief intervention for teens ongoing—Bernstein paper only published study
  • Incorporation of technology in screener is key, but technology changes quickly
  • Screening for prescription drug abuse calls for different approach—no one has studied yet
  • American Academy of Pediatrics will be releasing a policy statement on SBI using CRAFFT and brief advice at the end of summer
  • NIAAA will be releasing their adolescent screen at the end of the summer—not based on CRAFFT

Future Directions

  • Research
    • SValidation of CRAFFT prescreen
    • SBI for prescription drug abuse
    • Long-term trajectories for kids who screen positive on existing screens—for USPSTF
  • NIDA adolescent screen???